Across Europe, governments are navigating one of the most complex public health challenges of our time: how to regulate emerging nicotine products while protecting youth, safeguarding consumers, and achieving long-term health goals. At the Global Institute for Novel Nicotine (GINN), we recognize that these concerns are legitimate. Our goal is not to challenge regulation, but…
For decades, smoking has remained one of the leading causes of preventable death worldwide. Despite countless awareness campaigns and cessation programs, millions of adults continue to smoke, often because nicotine addiction makes quitting extremely difficult. However, not all nicotine use carries the same level of risk, and understanding this distinction is essential to reducing harm.…
Recent reporting from Vejpkollen highlights a growing clash between Sweden and Brussels over proposed EU tax reforms that could dramatically reshape the nicotine pouch market. At the core of the dispute is a question of principle: should safer nicotine alternatives be taxed in the same way as cigarettes, or should taxation reflect their much lower…
As nicotine pouches continue to gain popularity as a smoke-free alternative for adult consumers, understanding their composition has become increasingly important. Unlike traditional tobacco products, nicotine pouches are tobacco-leaf free, relying on plant-based fibers and carefully selected ingredients to deliver nicotine effectively and consistently. Below is a breakdown of the six main ingredient categories typically…
The World Health Organization’s new Global Report on Tobacco Trends 2000–2024 paints a complex picture: while smoking rates continue to fall, one in five adults worldwide still uses tobacco. Between 2000 and 2024, the global number of tobacco users declined from 1.38 billion to 1.2 billion, an impressive 120 million fewer smokers since 2010. Yet,…
A new, independently conducted clinical study in Experimental and Clinical Psychopharmacology offers rare, high-quality evidence on how oral nicotine pouches perform for people who already use smokeless tobacco (SLT) and why nicotine content is the hinge on which substitution success turns. What the study asked and why it matters Alisha Eversole and colleagues at Virginia…
At InterTabac, GINN’s Phil Hudson sat down with Hannu Karvonen, representing Denssi nicotine pouches, a Finnish brand making waves in Europe and beyond. In their conversation, Karvonen shared how Denssi is balancing product innovation, global expansion, and new category development to meet changing consumer demands. From Finland to the World Denssi’s story begins in Finland,…
At InterTabac 2025, GINN’s Phil Hudson sat down with Shivam Bihani, co-founder of MYNT Nicotine Pouches, to discuss the company’s origins, market growth, and vision for the future of oral nicotine. The conversation revealed how MYNT, founded in 2020 in Gujarat, India, has quickly become a global player in tobacco harm reduction. From India to…
Policies meant to restrict access to nicotine pouches are turning out to be counterproductive, especially for workers, whose access to tobacco alternatives is already constrained by time, location, and economic pressures. In New Brunswick, Canada, a construction worker’s story powerfully illustrates the human cost when safer options are forced off convenience shelves and buried behind…
At the New Approaches Summit 2025, the conversation around oral pouches moved beyond nicotine. What began as a harm reduction innovation has now evolved into a platform with potential far beyond smoking alternatives. Oral pouches, once defined by snus and nicotine, are being reimagined as discreet, fast-acting vehicles for functional microdosing and even emerging therapeutic…